Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation

Biochemical and Biophysical Research Communications

Volumn 457, Issue 1, 2015, Pages 23-30

  Fukuda, Kazuki ^a   Matsumura, Takeshi ^a   Senokuchi, Takafumi ^a   Ishii, Norio ^a   Kinoshita, Hiroyuki ^a   Yamada, Sarie ^a   Murakami, Saiko ^a   Nakao, Saya ^b   Motoshima, Hiroyuki ^a   Kondo, Tatsuya ^a   Kukidome, Daisuke ^a   Kawasaki, Shuji ^a   Kawada, Teruo ^c   Nishikawa, Takeshi ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b PREFECTURAL UNIVERSITY OF KUMAMOTO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; COX 2; PPAR ; Smooth muscle cell; Statin

Indexed keywords

APOLIPOPROTEIN E; CD36 ANTIGEN; CHOLESTEROL; CYCLOOXYGENASE 2; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PITAVASTATIN; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; LIPOPOLYSACCHARIDE; MONOUNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANTI ATHEROSCLEROTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; AORTA; ATHEROSCLEROSIS; C57BL MOUSE; CELL MOTION; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY;

MUS;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FATTY ACIDS, MONOUNSATURATED; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPOPOLYSACCHARIDES; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PPAR GAMMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921641586     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.12.063     Document Type: Article

References (35)

1. C.J. Vaughan, A.M. Gotto, C.T. Basson, The evolving role of statins in the management of atherosclerosis, J. Am. Coll. Cardiol. 35 (2000) 1-10.
2. M. Takemoto, J.K. Liao, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1712-1719.
3. R.S. Rosenson, C.C. Tangney, Antiatherothrombotic properties of statins: implications for cardiovascular event reduction, JAMA 279 (1998) 1643-1650.
4. U. Laufs, V. La Fata, J. Plutzky, J.K. Liao, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, Circulation 97 (1998) 1129-1135.
5. C. Weber, W. Erl, K.S. Weber, P.C. Weber, HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia, J. Am. Coll. Cardiol. 30 (1997) 1212-1217.
6. T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, et al., Statins suppress oxidized low-density lipoprotein-induced macrophage proliferation by inactivation of small G protein-p38 MAPK pathway, J. Biol. Chem. 280 (2005) 6627-6633.
7. J.K. Willaims, G. Sukhova, D. Herrington, P. Libby, Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys, J. Am. Coll. Cardiol. 31 (1998) 684-691.
8. M. Aikawa, E. Rabkin, Y. Okada, S.J. Voglic, et al., Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization, Circulation 97 (1998) 2433-2444.
9. S. Colli, S. Eligini, M. Lalli, M. Camera, et al., Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis, Arterioscler. Thromb. Vasc. Biol. 17 (1998) 265-272.
10. M.R. Soma, E. Donetti, C. Parolini, et al., HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits, Arterioscler. Thromb. 13 (1993) 571-578.
11. E.D. Rosen, B.M. Spiegelman, PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth, J. Biol. Chem. 276 (2001) 37731-37734.
12. G.A. Francis, J.S. Annicotte, J. Auwerx, PPAR agonists in the treatment of atherosclerosis, Curr. Opin. Pharmacol. 3 (2003) 186-191.
13. A.C. Li, K.K. Brown, M.J. Silvestre, et al., Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J. Clin. Invest. 106 (2000) 523-531.
14. M. Yano, T. Matsumura, T. Senokuchi, N. Ishii, et al., Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages, Circ. Res. 100 (2007) 1442-1451.
15. M. Igata, H. Motoshima, K. Tsuruzoe, K. Kojima, et al., Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression, Circ. Res. 97 (2005) 837-844.
16. D. Kukidome, T. Nishikawa, K. Sonoda, K. Imoto, et al., Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells, Diabetes 55 (2006) 120-127.
17. T. Matsumura, H. Kinoshita, N. Ishii, et al., Telmisartan exerts anti-atherosclerotic effects by activating PPARγ in macrophages, Arterioscler. Thromb. Vasc. Biol. 31 (2011) 1268-1275.
18. K. Taketa, T. Matsumura, M. Yano, N. Ishii, et al., Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-α (PPARα) and PPARγ through MAPK-dependent COX-2 expression in macrophages, J. Biol. Chem. 283 (2008) 9852-9862.
19. I.F. Charo, M.B. Taubman, Chemokines in the pathogenesis of vascular disease, Circ. Res. 95 (2004) 858-866.
20. X. Yang, D. Coriolan, V. Murthy, et al., Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling, Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H1069-H1076.
21. H. Hao, G. Gabbiani, M.L. Bochaton-Piallat, Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1510-1520.
22. P. Calabrò, E.T. Yeh, The pleiotropic effects of statins, Curr. Opin. Cardiol. 20 (2005) 541-546.
23. R.J. Aiello, P.A. Bourassa, S. Lindsey, et al., Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice, Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1518-1525.
24. L. Gu, Y. Okada, S.K. Clinton, et al., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice, Mol. Cell 2 (1998) 275-281.
25. K. Yasunari, K. Maeda, M. Minami, J. Yoshikawa, HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress, Arterioscler. Thromb. Vasc. Biol. 21 (2001) 937-942.
26. M. Jiang, H. Bujo, Y. Zhu, et al., Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells, Biochem. Biophys. Res. Commun. 348 (2006) 1367-1377.
27. B. Chandrasekar, S. Mummidi, L. Mahimainathan, et al., Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin, J. Biol. Chem. 281 (2006) 15099-15109.
28. M. Raiteri, L. Arnaboldi, P. McGeady, et al., Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation, J. Pharmacol. Exp. Ther. 281 (1997) 1144-1153.
29. W.W. Jr Stark, M.A. Blaskovich, B.A. Johnson, et al., Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells, Am. J. Physiol. 275 (1998) L55-L63.
30. U. Laufs, D. Marra, K. Node, J.K. Liao, 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1), J. Biol. Chem. 274 (1999) 21926-21931.
31. S.T. de Dios, D. Bruemmer, R.J. Dilley, et al., Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation, Circulation 107 (2003) 2548-2550.
32. R.E. Law, S. Goetze, X.P. Xi, et al., Expression and function of PPARgamma in rat and human vascular smooth muscle cells, Circulation 101 (2000) 1311-1318.
33. D. Meredith, M. Panchatcharam, S. Miriyala, et al., Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling, Arterioscler. Thromb. Vasc. Biol. 29 (2009) 465-471.
34. K. Nakamura, T. Sasaki, X.W. Cheng, et al., Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation, Atherosclerosis 206 (2009) 355-361.
35. Z. Li, M. Iwai, L. Wu, et al., Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis, Hypertension 44 (2004) 758-763.